Acute Pancreatitis Clinical Trial
Official title:
Exploring the Mechanism of Severe Acute Pancreatitis Based on Metagenomics, Metabolomics and Proteomics
The goal of this observational study is to learn about the biomarkers and mechanisms of severe acute pancreatitis in 30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis, and 86 patients of severe acute pancreatitis. The main question it aims to answer are: • The relationship between changes in gut microbiota and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), and the screening and validation of biomarkers that can be used for early prediction of disease severity. • Analyze the relationship between changes in blood composition and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), screen and verify biomarkers that can be used for early prediction of disease severity. Blood and fecal samples from the healthy control group and diagnosed patients will be collected.
Status | Not yet recruiting |
Enrollment | 176 |
Est. completion date | December 9, 2026 |
Est. primary completion date | March 9, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Patients group: ? Age between 18 and 75 years old; ? Within 72 hours of AP onset; ? AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria. Healthy control group: - Age between 18 and 75 years old; ? No history of acute pancreatitis; ? Routine laboratory tests such as blood routine and fecal routine are normal. Exclusion Criteria: - Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment; - Pregnant and lactating women; - Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS; - Chronic pancreatitis, pancreatic cancer; ? Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ? Unsigned informed consent form. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Nanchang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composition of gut microbiota | The gut microbiota plays an important role in protecting the intestinal barrier, regulating metabolism, and participating in immune responses in the human body, and is an important component of the gut ecosystem. | through study completion, an average of 1 year | |
Primary | Composition of gut metabolites | Metabolites can reveal the intrinsic correlation between metabolic products and physiological and pathological changes in the body, thereby achieving recognition of the overall state of the body. | through study completion, an average of 1 year | |
Primary | Composition of metabolites in plasma | Metabolites can reveal the intrinsic correlation between metabolic products and physiological and pathological changes in the body, thereby achieving recognition of the overall state of the body. | through study completion, an average of 1 year | |
Primary | composition of proteins in plasma | Proteins are an important material foundation for life activities and the main executors of life processes such as cell proliferation, differentiation, aging, and death. | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05410795 -
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
|
||
Recruiting |
NCT04195347 -
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
|
Phase 1/Phase 2 | |
Completed |
NCT04735055 -
Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
|
||
Completed |
NCT02928718 -
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
|
||
Terminated |
NCT02885441 -
Treatment of Acute Pancreatitis With Ketorolac
|
Phase 4 | |
Completed |
NCT02563080 -
Pancreatic Exocrine Insufficiency in Acute Pancreatitis
|
||
Recruiting |
NCT01626911 -
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
|
N/A | |
Completed |
NCT01507766 -
The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis
|
Phase 4 | |
Completed |
NCT04901949 -
The Course of Acute Pancreatitis in Patients With Different BMI Groups
|
||
Recruiting |
NCT04814693 -
Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
|
N/A | |
Completed |
NCT02743364 -
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
|
Phase 2 | |
Recruiting |
NCT05281458 -
Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections
|
N/A | |
Not yet recruiting |
NCT04990336 -
Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
|
N/A | |
Not yet recruiting |
NCT03259880 -
Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals
|
N/A | |
Completed |
NCT02543658 -
Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
|
Phase 2 | |
Recruiting |
NCT06023771 -
Invasive Intervention of Local Complications of Acute Pancreatitis
|
||
Not yet recruiting |
NCT05501314 -
Remote Home Monitoring Acute Pancreatitis
|
N/A | |
Completed |
NCT02897206 -
Imipenem Prophylaxis in Patients With Acute Pancreatitis
|
Phase 4 | |
Recruiting |
NCT03634787 -
Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
|
||
Active, not recruiting |
NCT04989166 -
Effect of Nano-curcumin Supplementation in Acute Pancreatitis
|
N/A |